Médecins Sans Frontières & Gilead Sciences

Médecins Sans Frontières: Médecins Sans Frontières (Doctors Without Borders) is actively responding to the Ebola outbreak, highlighting the worsening insecurity and catastrophic hygiene conditions in displacement sites.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Médecins Sans Frontières: Set up a training center in Kenya and provides emergency care in DRC.

Gilead Sciences: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.

Médecins Sans Frontières: Médecins Sans Frontières (MSF) has warned that the Ebola outbreak is spreading faster than the response, calling for immediate expansion of testing, faster deployment of aid workers, and sustained access for medical supplies.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

Médecins Sans Frontières: MSF urged Gilead to expand access to lenacapavir, highlighting affordability concerns.

Gilead Sciences: Facing pressure to expand access to lenacapavir; its pricing and licensing decisions are under scrutiny.

Médecins Sans Frontières: Médecins Sans Frontières (Doctors Without Borders) teams have identified suspected Ebola cases in Bunia hospitals, but found no available isolation wards, illustrating the overwhelmed healthcare infrastructure.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.